The estimated Net Worth of William P Sheridan is at least $6.18 Миллион dollars as of 10 March 2022. William Sheridan owns over 161,139 units of Biocryst Pharmaceuticals stock worth over $293,384 and over the last 16 years he sold BCRX stock worth over $4,823,970. In addition, he makes $1,067,180 as Senior Vice President и Chief Medical Officer at Biocryst Pharmaceuticals.
William has made over 17 trades of the Biocryst Pharmaceuticals stock since 2009, according to the Form 4 filled with the SEC. Most recently he sold 161,139 units of BCRX stock worth $2,720,026 on 10 March 2022.
The largest trade he's ever made was exercising 163,573 units of Biocryst Pharmaceuticals stock on 27 May 2021 worth over $871,844. On average, William trades about 14,045 units every 81 days since 2008. As of 10 March 2022 he still owns at least 37,954 units of Biocryst Pharmaceuticals stock.
You can see the complete history of William Sheridan stock trades at the bottom of the page.
Dr. William P. Sheridan serves as Senior Vice President, Chief Medical Officer of the Company. Dr. Sheridan joined BioCryst in July 2008 as its Senior Vice President and Chief Medical Officer. Dr. Sheridan spent 15 years in drug development at Amgen Pharmaceuticals, Inc., most recently as Vice President of North American Medical Affairs from March 2007 to November 2007, prior to joining the Company. Dr. Sheridan organized and led Amgen’s U.S. Medical Affairs function, making significant contributions to the successful launch of many compounds, including Aranesp®, Enbrel®, Kineret®, Neulasta® and Sensipar®. In addition to his most recent position at Amgen, Dr. Sheridan served at the Vice President level in International Medical Affairs, from March 2005 to February 2007; Global Health Economics, from January 2004 to January 2005; and Outcomes Research, U.S. Medical Affairs and Product Development from January 2002 to December 2003. Prior to joining Amgen, Dr. Sheridan practiced medicine at the Royal Melbourne Hospital in Victoria, Australia as Head of the Bone Marrow Transplant Service. He earned his MB BS degree (M.D. equivalent) at the University of Melbourne in Victoria. He is a board-certified fellow of the Royal Australasian College of Physicians, with a sub-specialty in hematology and medical oncology. After leaving Amgen in November 2007 and prior to joining the Company, Dr. Sheridan served as an independent consultant for pharmaceutical companies, including BioCryst.
As the Senior Vice President и Chief Medical Officer of Biocryst Pharmaceuticals, the total compensation of William Sheridan at Biocryst Pharmaceuticals is $1,067,180. There are 5 executives at Biocryst Pharmaceuticals getting paid more, with Jon Stonehouse having the highest compensation of $2,284,300.
William Sheridan is 65, he's been the Senior Vice President и Chief Medical Officer of Biocryst Pharmaceuticals since 2008. There are 7 older and 14 younger executives at Biocryst Pharmaceuticals. The oldest executive at Biocryst Pharmaceuticals Inc. is Robert Ingram, 77, who is the Independent Chairman of the Board.
William's mailing address filed with the SEC is 4505 EMPEROR BLVD., SUITE 200, DURHAM, NC, 27703.
Over the last 24 years, insiders at Biocryst Pharmaceuticals have traded over $76,362,383 worth of Biocryst Pharmaceuticals stock and bought 4,042,003 units worth $20,848,654 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Brothers Life Sciences Capi... и Carl L Gordon. On average, Biocryst Pharmaceuticals executives and independent directors trade stock every 31 days with the average trade being worth of $542,329. The most recent stock trade was executed by Amy E Mc Kee on 24 June 2024, trading 8,600 units of BCRX stock currently worth $54,352.
biocryst pharmaceuticals, a biotechnology company, designs, optimizes and develops novel small-molecule drugs that block key enzymes involved in infectious and rare diseases. founded in 1986, biocryst has more than 50 employees and is experiencing continued growth. the company’s headquarters are located in research triangle park, north carolina and its discovery center of excellence is in birmingham, alabama. with expertise in drug discovery, clinical development, regulatory affairs and product commercialization, we continue to advance our clinical programs and to generate new compounds from our own discovery engine. we are proud of our culture of engagement and accountability that rewards people for innovative thinking and achievement of key objectives. the commitment of biocryst remains unchanged. we continue to be passionate about developing and marketing novel therapeutics for patients with rare and serious diseases.
Biocryst Pharmaceuticals executives and other stock owners filed with the SEC include: